Merck released financial results for the first quarter of 2018 that show a strong start to the year with $10.0 billion in worldwide sales, an increase in 6% and 3% positive impact from foreign exchange.
Editor's Note: This article originally appeared on Merck's website.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2018.
“Merck had a strong start to the year driven by KEYTRUDA, GARDASIL, BRIDION and Animal Health,” said Kenneth C. Frazier, Merck Chairman and CEO. “This provides good momentum as we continue to execute on our pillars of growth and look to deliver innovative medicines and vaccines that address unmet needs for patients around the world.”
click here to continue>>
News from our partners